What the semaglutide heart failure trial found — and what it means for you

You've been told your heart failure is 'the preserved type', here's why that matters for this trial

HFpEF accounts for roughly half of all heart failure cases in the UK, yet until recently no medicine had convincingly shown it could reduce symptoms at scale. The heart pumps normally but the muscle stiffens and fills poorly, and obesity makes it worse by increasing filling pressures and inflammation. That is the precise population STEP-HF recruited.

Over 52 weeks, participants taking semaglutide 2.4mg once weekly scored around 7 points better on the Kansas City Cardiomyopathy Questionnaire (a validated, patient-reported symptom and quality-of-life tool) compared with those on placebo. A 5-point change is considered clinically meaningful. Six-minute walk distance also improved significantly. These are hard endpoints, not just averages drifting in the same direction. The study did not find a statistically significant reduction in hospitalisations for heart failure or deaths, so claims that semaglutide 'prevents cardiac events' in HFpEF go beyond what STEP-HF showed. That nuance matters when interpreting headlines.

If you want to understand how semaglutide interacts with cardiac function more broadly, the relationship between semaglutide and heart health is a useful starting point before returning to the trial specifics.

The weight-loss mechanism almost certainly matters, but it probably isn't the whole story

Losing around 13% of body weight in a year would itself be expected to ease HFpEF. Reduced adipose tissue lowers circulating inflammatory markers, reduces ventricular filling pressure and lightens the mechanical load on a heart that is already struggling to relax. Researchers acknowledged this confounding in their analysis.

What makes STEP-HF interesting is that symptom improvement appeared to exceed what weight loss alone would predict, which has led some cardiologists to speculate about direct anti-inflammatory or natriuretic effects of GLP-1 receptor agonism. Those mechanisms are still being studied; they are not established. The SELECT trial (a separate, much larger cardiovascular outcomes study in over 17,500 adults with pre-existing cardiovascular disease) did find a significant reduction in major adverse cardiovascular events with semaglutide 2.4mg, lending broader context to cardiac-related interest in this drug. For the specific question of semaglutide in heart failure with reduced ejection fraction, the picture is more complicated and the evidence thinner, that is a different condition with a different pathophysiology.

None of this changes the regulatory status. Semaglutide is licensed in the UK as Wegovy for weight management in eligible adults, not as a cardiology medicine. NICE's recommendation under TA875 reflects this: semaglutide for weight management, within specialist services, for up to two years, with a comorbidity profile and BMI threshold that a prescriber assesses.

What anyone with heart failure should do before starting Wegovy

Cardiac history is one of the clinical details our prescribers review at consultation. That isn't a formality. Heart failure can affect fluid balance, blood pressure and how someone tolerates rapid weight loss; a prescriber needs to know the type, severity and current treatment before making any decision. The process at nume means a GPhC-registered prescriber personally reads your consultation (not software) and will either approve, request further information, or advise you to discuss this with your cardiologist first.

If approved, the pen arrives via DPD the next working day in plain packaging, tracked to your phone, ready to start in the routine your prescriber outlines. Practical information on whether and how Wegovy can be used alongside an existing cardiac diagnosis is covered separately on whether you can take Wegovy with heart failure. Some people are also curious about semaglutide's effect on resting heart rate, which is a separate and legitimate question that the prescriber can address in context.

Cost is a practical consideration too. A summary of how Wegovy pricing works across UK providers explains what a legitimate private prescription includes, so you can make a genuinely informed comparison rather than just comparing headline numbers. For anyone ready to discuss their medical history with our team, checking eligibility takes a few minutes and the consultation is free.